Harmony Biosciences Acquires Epygenix Therapeutics For $35M With Development Milestone Payments Of $130M And There Is Potential Sales Milestone Payments Of $515M
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences acquires Epygenix Therapeutics for $35M, with potential development and sales milestone payments totaling $645M. EPX-100, their lead candidate for rare epilepsy conditions, is in a pivotal trial with topline data expected in 2026, indicating a significant market opportunity.
April 30, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences' acquisition of Epygenix Therapeutics for $35M, with additional milestone payments, positions HRMY in a potential billion-dollar rare epilepsy market.
The acquisition directly impacts HRMY by potentially expanding its product pipeline with EPX-100, a candidate in a pivotal trial for Dravet Syndrome, and planning for a Phase 3 trial for Lennox-Gastaut Syndrome. The significant investment and the potential for high milestone payments underscore the strategic importance of this acquisition for Harmony Biosciences, aiming at a substantial market opportunity in rare epilepsy treatments.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100